Abstract:PURPOSE:Pancreatic cancer is a highly aggressive disease that remains refractory to various chemotherapeutic agents. Because the proto-oncogene c-myc can modulate apoptosis in response to cytotoxic insults and is commonly overexpressed in pancreatic cancer, we investigated the value of c-myc as a potential modulator of cellular response to various chemotherapeutic agents.EXPERIMENTAL DESIGN:Stable overexpression or small interfering RNA (siRNA)-mediated knockdown of c-myc and restoration of cyclin D1 were done in the Ela-myc pancreatic tumor cell line. Cell viability after cisplatin treatment of c-myc-overexpressing, control, and siRNA-transfected cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and drug-induced apoptosis was measured by DNA fragmentation, sub-G(1), and poly(ADP-ribose) polymerase cleavage analyses. Protein expression profile after cisplatin treatment was determined by Western blotting and DNA binding activity of nuclear factor-kappaB was examined by electrophoretic mobility shift assay.RESULTS:Ectopic overexpression of c-myc in murine and human pancreatic cancer cell lines, Ela-myc and L3.6pl, respectively, resulted in increased sensitivity to cisplatin and other chemotherapeutic drugs. Increased sensitivity to cisplatin in c-myc-overexpressing cells was due, in part, to the marked increase in cisplatin-induced apoptosis. Conversely, down-regulation of c-myc expression in stable c-myc-overexpressing cells by c-myc siRNA resulted in decreased sensitivity to cisplatin-induced cell death. These results indicate an important role of c-myc in chemosensitivity of pancreatic cancer cells. The c-myc-induced cisplatin sensitivity correlated with inhibition of nuclear factor kappaB activity, which was partially restored by ectopic cyclin D1 overexpression.CONCLUSIONS:Our results suggest that the c-myc-dependent sensitization to chemotherapy-induced apoptosis involves suppression of cyclin D1 expression and nuclear factor kappaB activity.

Calcineurin-mediated dephosphorylation enhances the stability and transactivation of c-Myc

C-Myc-induced Chemosensitization is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-Kappa B Activity in Pancreatic Cancer Cells.

Ire1 Alpha Rnase-Dependent Lipid Homeostasis Promotes Survival In Myc-Transformed Cancers

Calcineurin-mediated dephosphorylation stabilizes E2F1 protein by suppressing binding of the FBXW7 ubiquitin ligase subunit

CRL2 KLHDC3 and CRL1 Fbxw7 cooperatively mediate c-Myc degradation

Stabilization of the C-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma.

MYC shapes ER-mitochondria calcium transfer by directly targeting : implications for MYC-induced safeguard mechanisms and cancer

Usp16-Mediated Deubiquitination Of Calcineurin A Controls Peripheral T Cell Maintenance

MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability

SUMO protease SENP1 deSUMOylates and stabilizes c-Myc

Calcineurin inactivation inhibits pyruvate dehydrogenase complex activity and induces the Warburg effect

Target c-Myc to treat pancreatic cancer

RCAN1-mediated Calcineurin Inhibition As a Target for Cancer Therapy

A c-Myc–SIRT1 feedback loop regulates cell growth and transformation

Transcriptional Amplification in Tumor Cells with Elevated c-Myc

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

C-Myc Promotes Cholangiocarcinoma Cells to Overcome Contact Inhibition Via the Mtor Pathway

Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival

Myc inhibition impairs autophagosome formation

Altering MYC phosphorylation in the epidermis increases the stem cell population and contributes to the development, progression, and metastasis of squamous cell carcinoma

Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms